We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
athenahealth Unveils athenaInsight, Focuses on Opioid Abuse
Read MoreHide Full Article
athenahealth Inc. recently introduced athenalnsight, a daily news hub which will keep track of the activities of 80,000 healthcare providers and 81 million ‘de-identified patients’. This will help share comprehensive information pertaining to the healthcare industry with a much broader audience.
With this launch, athenahealth is set to look into factors that are affecting the nation’s ‘high-performing health systems’ and ‘public health wellness’, thanks to threats from Zika, flu virus and opioid (a painkiller drug).
Notably, opioid abuse is a mounting problem in the U.S. and athenahealth has collaborated with the Centers for Disease Control and Prevention (CDC) to launch the ‘Guideline for Prescribing Opioids for Chronic Pain’ to deal with this crisis. In fact, the company, with its newly launched platform, plans to carry out detailed investigations, conduct expert interviews and study the varied aspects of the crisis (with the help of data-backed charts and relevant infographics).
Coming to share price movement, athenahealth gained a nominal 0.5% to close at $121.64 following the news.
We believe athenaInsight will be the ideal platform to address the issue of ‘information asymmetries’ in the American healthcare industry. The latest development promises to provide a clear picture of healthcare industry data and leadership insights of the care givers which is expected to exclusively fortify the company’s position in the Healthcare & Information Technology (HCIT) market.
Notably, the HCIT market has gained much investor’s focus of late on its forecast to reach a worth of $228.7 billion by 2020, at a CAGR of 13.4% (Markets And Markets), a major positive for athenahealth.
athenahealth has already marked its prominence as an Electronic Health Record (EHR) usability leader. In fact, the company is enhancing its growth trajectory with a strong product portfolio, growing physician base, solid R&D focus and unique business model. In addition to these, the recent development is a significant milestone for the company in our view.
Zacks Rank & Key Picks
Currently, athenahealth has a Zacks Rank #3 (Hold).
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
athenahealth Unveils athenaInsight, Focuses on Opioid Abuse
athenahealth Inc. recently introduced athenalnsight, a daily news hub which will keep track of the activities of 80,000 healthcare providers and 81 million ‘de-identified patients’. This will help share comprehensive information pertaining to the healthcare industry with a much broader audience.
With this launch, athenahealth is set to look into factors that are affecting the nation’s ‘high-performing health systems’ and ‘public health wellness’, thanks to threats from Zika, flu virus and opioid (a painkiller drug).
Notably, opioid abuse is a mounting problem in the U.S. and athenahealth has collaborated with the Centers for Disease Control and Prevention (CDC) to launch the ‘Guideline for Prescribing Opioids for Chronic Pain’ to deal with this crisis. In fact, the company, with its newly launched platform, plans to carry out detailed investigations, conduct expert interviews and study the varied aspects of the crisis (with the help of data-backed charts and relevant infographics).
Coming to share price movement, athenahealth gained a nominal 0.5% to close at $121.64 following the news.
ATHENAHEALTH IN Price
ATHENAHEALTH IN Price | ATHENAHEALTH IN Quote
Our Take
We believe athenaInsight will be the ideal platform to address the issue of ‘information asymmetries’ in the American healthcare industry. The latest development promises to provide a clear picture of healthcare industry data and leadership insights of the care givers which is expected to exclusively fortify the company’s position in the Healthcare & Information Technology (HCIT) market.
Notably, the HCIT market has gained much investor’s focus of late on its forecast to reach a worth of $228.7 billion by 2020, at a CAGR of 13.4% (Markets And Markets), a major positive for athenahealth.
athenahealth has already marked its prominence as an Electronic Health Record (EHR) usability leader. In fact, the company is enhancing its growth trajectory with a strong product portfolio, growing physician base, solid R&D focus and unique business model. In addition to these, the recent development is a significant milestone for the company in our view.
Zacks Rank & Key Picks
Currently, athenahealth has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical instrument sector include USANA Health Sciences Inc. (USNA - Free Report) , Edwards Lifesciences Corp (EW - Free Report) and Amphastar Pharmaceuticals Inc (AMPH - Free Report) . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>